Targacell

A non-invasive stem cell delivery system using proprietary proteins to repair damaged hearts & control damaging immune responses

Innovative Universal Delivery Technology

WHAT IS TARGACELL ?

TargaCell is a preclinical stem cell delivery company that can deliver 10X more stem cells to the heart and retain them there to dramatically improve the repair of damaged heart tissue resulting from a heart attack.

– Catherine Phillips, PhD, CEO/CSO

[ Read The Welcome Letter from our CEO ]

DISCOVER US

Our biologics dampen the concurrent inflammatory immune responses that impede the regenerative process, promoting organ repair.

0 X

Proprietary biologics that deliver 10X the number of stem cells

0 M

Over $8.5M investment by federal, private, academic grants and innovator contributions.

The Problem

The initial focus is addressing cellular therapy's major impediment to completely repairing damage from a heart attack and preventing progression to heart failure and death: It is that not enough stem cells are delivered and retained in the heart to make repair efficient!

The Technology

TargaCell developed and is refining an efficient stem cell delivery technology using our proprietary biologics that deliver 10X the number of stem cells to the heart and retain them long enough to repair damage and restore function. TargaCell's compounds are first-in-class, premium biologics.

Intellectual Property

TargaCell owns its intellectual property portfolio for its biologic products consisting of two issued patents, with an additional provisional in Fall/Winter 2022 on inflammatory syndromes.Complementing TargaCell's trade secrets, we are pursuing a biologics regulatory strategy to attain 12-year market exclusivity in US and EU.

TargaCell Corp.

TargaCell Corporation, Chicago-based biotech, is dedicated to repairing organ damage caused by disease to recover function & restore quality of life through improved non-invasive, targeted delivery of regenerative cells to specific organs.

Testimonials

Testimonials About TargaCell

Catheter delivery will not be the future of stem cell delivery for heart regeneration…too few cells can be delivered and retained to have this theraphy reach its potential. Your technology has the potential to do this…

Douglas Losordo, MD

Executive Vice-President for Global Research & Development & Chief Medical Officer, Caladrius; (while Prof. Cardiology Northwestern University Feinberg School of Medicine)

The [TargaCell] non-invasive delivery procedure would make it much easier to enroll patients {in clinical trials}. On current methods, “… where [do] these cells go once they are injected into the wall because clearly most of them don’t remain there for very long.

Gary Schaer, MD

Professor Cardiology & Director of Translational Medicine Research, Rush University, Chicago, IL

TargaCell